Hepatic Cell News 2.09 March 9, 2018 | |
| |
TOP STORYRecent data demonstrated a liver tumor-suppressing role for Shp2, as ablating Shp2 in hepatocytes aggravated hepatocellular carcinoma induced by chemical carcinogen or Pten loss. Researchers investigated the effect of Shp2 deficiency on liver tumorigenesis driven by classical oncoproteins c-Met, β-catenin and PIK3CA. [J Hepatol] Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)USP27-Mediated Cyclin E Stabilization Drives Cell Cycle Progression and Hepatocellular Tumorigenesis Scientists identified ubiquitin-specific peptidase 27 (USP27) as a Cyclin E interactor. They found that USP27 promoted Cyclin E stability by negatively regulating its ubiquitination. [Oncogene] Full Article Galunisertib modulated the expression of stemness-related genes only in the invasive hepatocellular carcinoma (HCC) cells inducing a decreased expression of CD44 and THY1. Galunisertib also reduced the stemness-related functions of invasive HCC cells decreasing the formation of colonies, liver spheroids and invasive growth ability. [Cell Death Dis] Full Article Researchers found that the expression of E74-like ETS transcription factor 3 (ELF3), a member of the E-twenty-six family of transcription factors, was increased in hepatocellular carcinoma (HCC) tissues, and that ELF3 overexpression was associated with poor prognoses for HCC patients. [Cell Death Dis] Full Article The authors analyzed the suitability of induced pluripotent stem cell-derived hepatocyte-like cells as a physiologically relevant model to study hepatitis C virus replication in vitro. [Sci Rep] Full Article Scientists revealed that nuclear form of sterol regulatory element–binding protein (SREBP)-1a (nBP1a)/pyruvate kinase M2 interaction activates lipid metabolism genes in cancer cells and that Thr-59 phosphorylation of SREBP-1a plays an important role in cancer cell proliferation. [J Biol Chem] Full Article Investigators induced hepatic differentiation of human induced pluripotent stem cells under perfusion conditions and performed functional comparisons with fresh human precision cut liver slices, an excellent benchmark for the human liver in vivo. [J Tissue Eng Regen Med] Abstract A Novel Flow Cytometry Tool for Fibrosis Scoring through Hepatic Stellate Cell Differentiation Researchers characterized hepatic stellate cell differentiation using a flow cytometry tool for fibrosis scoring. [Cytometry A] Abstract The authors investigated the therapeutic effects of propranolol on carbon tetrachloride (CCl4)-induced liver fibrosis in a mouse model and the intrinsic mechanisms underlying those effects. [Hum Pathol] Abstract | |
| |
REVIEWSSchistosome-Induced Fibrotic Disease: The Role of Hepatic Stellate Cells Scientists discuss recent advances in hepatic stellate cell (HSC) biology and the role of HSCs in hepatic schistosomiasis. [Trends Parasitol] Abstract Hepatitis B Virus-Associated Hepatocellular Carcinoma and Hepatic Cancer Stem Cells Researchers present the basics about hepatitis B virus infection and hepatocarcinogenesis. They discuss studies describing the mutational landscape of liver cancers and how epigenetic mechanisms likely orchestrate cellular reprograming of hepatocytes to enable formation of human cancer stem cells. [Genes (Basel)] Full Article Visit our reviews page to see a complete list of reviews in the hepatic cell research field. | |
| |
INDUSTRY NEWSEisai Co., Ltd. and Merck announced that the companies have agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA®, an orally available tyrosine kinase inhibitor discovered by Eisai. [Eisai Co., Ltd.] Press Release Immuron Reports Positive Results in NASH Clinical Trial Immuron Limited announced the topline results of its IMM-124E Phase II non-alcoholic steato-hepatitis (NASH) clinical study. [Immuron Limited] Press Release CERENIS Therapeutics announced the approval and the upcoming launch of the second Phase I study to assess the daily administration of increasing doses of CER-209 over a 28-day period in patients with a high risk of developing non-alcoholic steato-hepatitis (NASH) and/or non-alcoholic fatty liver disease (NAFLD). [Cerenis Therapeutics Inc.] Press Release MiNA Therapeutics announced the publication of pre-clinical data on its MTL-CEBPA program in which the compound was shown to promote disease reversal in several models of liver disease and to reduce tumor burden in a model of liver cancer. [MiNA Therapeutics] Press Release | |
| |
POLICY NEWSScientists Win and Lose in Texas Primary Contests Texas primary was the first test for scientists seeking seats in the U.S. House of Representatives, and the results were mixed. [ScienceInsider] Editorial Behavioral ‘Violations’ Cost Prominent Neuroscientist Positions at Columbia, HHMI Prominent Columbia University neuroscientist Tom Jessell, 66, has been fired for “serious [behavioral] violations” and the university is closing his lab, the New York City institution said in a statement. The Howard Hughes Medical Institute (HHMI) in Chevy Chase, Maryland, which effectively employed Jessell, a leader in understanding neural development, also terminated him as an investigator because he “violated HHMI policy,” according to a statement from the institute. [ScienceInsider] Editorial Police Probe of Brazilian Marijuana Researcher Sparks Protests A police investigation targeting Brazil’s most prominent marijuana researcher has ignited a wave of protest among scientists. They say that the move by authorities from the state of São Paulo threatens research freedoms at a time when science in the country faces severe problems because of draconian budget cuts. [Nature News] Editorial
| |
EVENTSNEW 6th Annual German Stem Cell Network (GSCN) Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Scientist – Viral Vectored Vaccines for Hepatitis Infections (University of Oxford) Postdoctoral Research Associate – Liver Diseases (University of Illinois at Chicago) Postdoctoral Scientist – Acute-on-Chronic Liver Failure (Foundation for Liver Research) Postdoctoral Research Scientist – Cancer Research (Cancer Research UK Beatson Institute) Global Clinical Lead – Oncology (AstraZeneca) Postdoctoral Research Scientist – Hepatocellular Carcinoma (Cancer Research UK Beatson Institute) Postdoctoral Fellowship – Translational Cancer Research (Lund University) Lectureship – Stem Cell Biology and Regenerative Medicine (University of Edinburgh) Postdoctoral Fellow – Liver Cancer Research (University of California, San Francisco) Postdoctoral Position – Liver Diseases (University of Illinois) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hepatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|